Marizomib

Drug Profile

Marizomib

Alternative Names: MRZ; NPI-0052; Salinosporamide A

Latest Information Update: 19 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nereus Pharmaceuticals
  • Developer Celgene Corporation; European Organisation for Research and Treatment of Cancer; Triphase Accelerator Corporation
  • Class Anti-inflammatories; Antineoplastics; Lactones; Pyrroles; Small molecules
  • Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glioblastoma
  • Phase II Multiple myeloma
  • No development reported Cancer; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 26 Jul 2018 Phase-III clinical trials in Glioblastoma (Combination therapy, First-line therapy, Newly diagnosed, Adjuvant therapy) in Spain, Norway (IV) (NCT03345095)
  • 26 Jul 2018 Phase-III clinical trials in Glioblastoma (Newly diagnosed, Combination therapy, Adjuvant therapy, First-line therapy) in Netherlands (IV) (NCT03345095)
  • 28 Jun 2018 No recent reports of development identified for preclinical development in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top